MedTrace Logo

MOTIV Study- Effect of Antidepressive Treatment by Escitalopram in Patients Undergoing Coronary Artery Bypass Grafting

NCT00243477 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 368

Last updated 2012-03-19

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of an antidepressive medication (Escitalopram), started preoperatively and given during 6 months, on 6-month and 1 year post-operative morbidity and mortality after coronary artery bypass grafting

Conditions

Interventions

DRUG

Escitalopram

Escitalopram 10mg or placebo once a day

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Hopital Jean Minjoz

    lead OTHER

Principal Investigators

  • Sidney Chocron, Prof · Department of Cardiac Surgery - Besancon - France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2011-02-28
Completion
2012-02-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243477 on ClinicalTrials.gov